Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TLR2 | O60603 | 2/20 | 0.55 |
| ▸ | MDM4 | O15151 | 2/20 | 0.52 |
| ▸ | TP53 | P04637 | 2/20 | 0.52 |
| ▸ | MDM2 | Q00987 | 6/20 | 0.50 |
| ▸ | CASP3 | P42574 | 2/20 | 0.46 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.46 |
| ▸ | SLC17A5 | Q9NRA2 | 1/20 | 0.45 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL29651368 | 1.00 | TLR2 (0.55) | TLR2MDM4TP53MDM2CASP3 | |
| SCHEMBL29750297 | 1.00 | TLR2 (0.55) | TLR2MDM4TP53MDM2CASP3 | |
| SCHEMBL13227676 | 1.00 | TLR2 (0.55) | TLR2MDM4TP53MDM2CASP3 | |
| SCHEMBL31217659 | 1.00 | TLR2 (0.55) | TLR2MDM4TP53MDM2CASP3 | |
| SCHEMBL1755686 | 1.00 | TLR2 (0.55) | TLR2MDM4TP53MDM2CASP3 | |
| SCHEMBL29401774 | 1.00 | TLR2 (0.55) | TLR2MDM4TP53MDM2CASP3 | |
| SCHEMBL29350848 | 1.00 | TLR2 (0.55) | TLR2MDM4TP53MDM2CASP3 | |
| SCHEMBL20592524 | 0.94 | MDM2 (0.54) | TLR2MDM4TP53MDM2CASP3 | |
| SCHEMBL20592527 | 0.94 | MDM2 (0.54) | TLR2MDM4TP53MDM2CASP3 | |
| SCHEMBL29759454 | 0.94 | MDM2 (0.54) | TLR2MDM4TP53MDM2CASP3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 51 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20240218022-A1 | ANTI-VISTA MACROCYCLIC PEPTIDES AND COMPOSITIONS | BRISTOL-MYERS SQUIBB COMPANY (US) | 2024-07-04 | — | — | US | disclosed |
| US-20230374034-A1 | NOVEL BICYCLIC COMPOUNDS | Prism BioLab Co., Ltd. (JP) | 2023-11-23 | — | — | US | disclosed |
| US-20230144653-A1 | 1,2,4-Oxadiazole Compounds as Inhibitors of CD47 Signalling Pathways | AURIGENE ONCOLOGY LIMITED (IN) | 2023-05-11 | — | — | US | disclosed |
| CN-115943151-A | Process for the preparation of GLP-1/glucagon dual agonists | 伊莱利利公司 | 2023-04-07 | — | — | CN | disclosed |
| CN-108794422-B | Heterocyclic compounds as PD-L1 inhibitors | 南京圣和药业股份有限公司 | 2022-07-01 | — | — | CN | disclosed |
| US-11331364-B2 | Use for JNK inhibitor molecules for treatment of various diseases | XIGEN INFLAMMATION LTD. (CY) | 2022-05-17 | — | — | US | disclosed |
| US-11319347-B2 | Peptide compound and method for producing same, composition for screening use, and method for selecting peptide compound | FUJIFILM CORPORATION (JP) | 2022-05-03 | — | — | US | disclosed |
| US-11149066-B2 | Thrombospondin 1-binding peptide | DAIICHI SANKYO COMPANY, LIMITED (JP) | 2021-10-19 | — | — | US | disclosed |
| US-20200131230-A1 | THROMBOSPONDIN 1-BINDING PEPTIDE | DAIICHI SANKYO COMPANY, LIMITED (JP) | 2020-04-30 | — | — | US | disclosed |
| US-20200093883-A1 | Use For JNK Inhibitor Molecules for Treatment of Various Diseases | XIGEN INFLAMMATION LTD. (CY) | 2020-03-26 | — | — | US | disclosed |
| US-20070004644-A1 | Mediators of reverse cholesterol transport for the treatment of hypercholesterolemia | SIRCAR JAGADISH C | 2007-01-04 | — | — | US | disclosed |
| US-20050137138-A1 | E2F activity-inhibiting compound | KYOWA HAKKO KOGYO CO., LTD (JP) | 2005-06-23 | — | — | US | disclosed |
| US-6713449-B1 | E2F activity inhibitory compounds | KYOWA HAKKO KOGYO CO., LTD. (JP) | 2004-03-30 | — | — | US | disclosed |
| US-20030055213-A1 | Endothelin-antagonizing peptide | TANAKA TAKEO (JP) | 2003-03-20 | — | — | US | disclosed |
| US-20030027218-A1 | PEPTIDES PROMOTING THE ACTIVATION OF LATENT TGF-BETA AND METHOD FOR SCREENING TGF-BETA ACTIVITY REGULATORS | KYOWA HAKKO KOGYO CO., LTD. (JP) | 2003-02-06 | — | — | US | disclosed |
| US-6194195-B1 | PURE CULTURE; FOR PRODUCTION OF HYPOTENSIVE AGENTS AND THERAPIES FOR ASTHMA, CEREBRAL APOPLEXY, ANGINA PECTORIS, ACUTE RENAL FAILURE, CARDIAC INFARCTION, AND CEREBRAL VASOSPASM | KYOWA HAKKO KOGYO CO., LTD. (JP) | 2001-02-27 | — | — | US | disclosed |
| EP-0989136-A1 | PEPTIDES HAVING CYCLIC STRUCTURES AND EXERTING P53 PROTEIN ACTIVTY-RESTORING EFFECT ON P53 PROTEIN MUTANTS | KYOWA HAKKO KOGYO CO., LTD. (JP) | 2000-03-29 | — | — | EP | disclosed |
| EP-0963999-A1 | E2F ACTIVITY INHIBITORY COMPOUNDS | KYOWA HAKKO KOGYO CO., LTD. (JP) | 1999-12-15 | — | — | EP | disclosed |
| EP-0922710-A1 | PEPTIDES PROMOTING THE ACTIVATION OF LATENT TGF-$g(b) AND METHOD FOR SCREENING TGF-$g(b) ACTIVITY REGULATORS | KYOWA HAKKO KOGYO CO., LTD. (JP) | 1999-06-16 | — | — | EP | disclosed |
| EP-0770623-A1 | NOVEL CALCITONIN DERIVATIVES | KYOWA HAKKO KOGYO CO., LTD. (JP) | 1997-05-02 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (8 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230374034-A1 | NOVEL BICYCLIC COMPOUNDS | NOTCH1, NOTCH2, HES1 | TLR2 3380/4885MDM4 4639/4885TP53 712/4885 |
| US-11149066-B2 | Thrombospondin 1-binding peptide | SERPINC1, TEK, ARGLU1 | TLR2 2737/4885MDM4 3675/4885TP53 4241/4885 |
| US-20200131230-A1 | THROMBOSPONDIN 1-BINDING PEPTIDE | SERPINC1, TEK, ARGLU1 | TLR2 2737/4885MDM4 3675/4885TP53 4241/4885 |
| US-20230144653-A1 | 1,2,4-Oxadiazole Compounds as Inhibitors of CD47 Signalling Pathways | CD47, HIF1AN, PIK3R5 | TLR2 955/4885MDM4 4119/4885TP53 1709/4885 |
| US-20070004644-A1 | Mediators of reverse cholesterol transport for the treatment of hypercholesterolemia | CETP, LDLR, NPC1L1 | TLR2 2440/4885MDM4 4496/4885TP53 4543/4885 |
| US-20240218022-A1 | ANTI-VISTA MACROCYCLIC PEPTIDES AND COMPOSITIONS | VIP, SGTA, NGLY1 | TLR2 3449/4885MDM4 4261/4885TP53 1583/4885 |
| US-11319347-B2 | Peptide compound and method for producing same, composition for screening use, and method for selecting peptide compound | VIP, NPPA, NGLY1 | TLR2 3116/4885MDM4 4154/4885TP53 1409/4885 |
| US-20030055213-A1 | Endothelin-antagonizing peptide | NPY1R, ECE1, EDNRB | TLR2 2129/4885MDM4 4129/4885TP53 4032/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.